Lantheus (LNTH) Expected to Announce Quarterly Earnings on Thursday

Lantheus (NASDAQ:LNTH) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Lantheus to post earnings of $1.17 per share and revenue of $367.0310 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Lantheus Price Performance

Shares of LNTH opened at $73.06 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The company’s fifty day moving average price is $66.89 and its 200-day moving average price is $59.47. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29. The firm has a market capitalization of $4.84 billion, a PE ratio of 30.70 and a beta of -0.08.

Analyst Ratings Changes

Several analysts have weighed in on LNTH shares. Mizuho boosted their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Finally, Truist Financial raised their price target on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Institutional Investors Weigh In On Lantheus

A number of hedge funds and other institutional investors have recently made changes to their positions in LNTH. Smartleaf Asset Management LLC lifted its stake in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Osterweis Capital Management Inc. purchased a new position in Lantheus in the second quarter valued at $36,000. Parallel Advisors LLC raised its position in shares of Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 298 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Lantheus during the 4th quarter worth about $39,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Lantheus during the 3rd quarter valued at about $55,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.